Alterity Therapeutics Limited (ATHE)
|Net Income (ttm)||-13.46M|
|Trading Day||July 29|
|Day's Range||1.30 - 1.33|
|52-Week Range||1.09 - 5.15|
Alterity Therapeutics Announces Publication of Data Demonstrating ATH434 is Neuroprotective and Improves Motor Function
MELBOURNE, Australia, July 15, 2021 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatm...
Alterity Therapeutics granted a new US patent targeting major neurodegenerative diseases including Alzheimer's and Pa...
MELBOURNE, Australia and SAN FRANCISCO , July 1, 2021 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") has today announced the granting of a new composition o...
Alterity Therapeutics Limited Received European Union Regulatory Guidance for ATH434 Phase 2 Clinical Trial
Highlights: Alterity receives positive guidance from the European Medicines Agency's Committee for Medicinal Products for Human Use on its Phase 2 clinical trial for Multiple System Atrophy. Concurrence...
Highlights: Michael J. Fox Foundation grants Alterity $US495K for Parkinson's disease research evaluation Strengthening profile at investment, scientific and clinical conferences Dr David Stamler appoin...
Alterity's Stock Is Trading Higher As ATH434 Preserves Neurons, Motor Performance In Animal Model With Neurodegenerat...
Alterity Therapeutics (NASDAQ: ATHE) has announced the presentation of expanded animal data to support the commercialization of its lead compound ATH434 in development to treat Parkinsonian disorders. D...
MELBOURNE, Australia and SAN FRANCISCO, Feb. 26, 2021 /PRNewswire/ -- Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), will present at the upcoming 7th International...
MELBOURNE, Australia, Dec. 21, 2020 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") has today announced it has been granted a licence by UniQuest, the commer...
As of 1:46 PM ET, the stock price of Alterity Therapeutics Ltd (NASDAQ: ATHE) (ASX: ATH) is trading up 153.48% at $2.92 (up from the previous close of $1.15). Why is this happening?
Alterity Therapeutics (ATHE) news for Monday includes approval of a new patent protecting its drugs pushing ATHE stock higher. The post Alterity Therapeutics News: 8 Things for ATHE Stock Investors to K...
Shares of Alterity Therapeutics Ltd (NASDAQ: ATHE) gap-opened Monday's session higher and are sustaining the gains. What Happened: The Australian biopharma said the U.S. Patent and Trademark Office has ...
The U.S.-listed shares of Alterity Therapeutics Ltd. rocketed 129.6% on massive volume in morning trading Monday, enough to be the biggest gainer among those listed on major U.S. exchanges, after the Au...
Alterity announces approval of US patent for next generation compounds to treat neurodegenerative diseases
MELBOURNE, Australia, Nov. 16, 2020 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") has today announced the allowance of a new composition of matter patent b...
MELBOURNE, Australia and SAN FRANCISCO, Oct. 26, 2020 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") today announced it has commenced enrolling patients wit...
Alterity Therapeutics Ltd. (NASDAQ: ATHE) stock more than doubled on Tuesday after the company announced new data for its lead drug candidate ATH434.
Alterity's stock nearly triples on heavy volume after update on study of treatment for MSA, Parkinson's
Shares of Alterity Therapeutics Ltd. ATHE, -7.53% nearly tripled (up 173%) toward a 3-year high on heavy volume in premarket trading Tuesday, after the therapeutic drugs developer said it will present p...
The shares of Alterity Therapeutics Ltd. (NASDAQ: ATHE) advanced in the after-hours session trading in New York on Monday and in the regular session in Sydney on Tuesday.
Highlights: FDA provides guidance for ATH434 development pathway Company compliant with minimum NASDAQ price End of period cash balance of $9.2M bolstered by $1.5M following issue of shares on 2 July ME...
Alterity Therapeutics shares are trading higher on Tuesday after the company announced it received a development pathway from its meeting with the FDA for ATH434.
Alterity Therapeutics Ltd. (NASDAQ: ATHE) says it has received an update from the U.S.
Alterity Therapeutics Limited researches and develops therapeutic drugs for the treatment of Parkinsonian's disease and other neurodegenerative diseases in Australia. The company's lead drug candidates is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 for used as an antimicrobial agent. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. The company was founded in 1997 and is based in Melbourne, A... [Read more...]
|Stock Exchange |
|Ticker Symbol |